Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
University of Wuerzburg
ClinicalTrials.gov Identifier:
NCT00227149
First received: September 23, 2005
Last updated: February 3, 2009
Last verified: February 2009
  Purpose

This is a long-term evaluation follow-up study of neurocognitive performance and emotional state in patients with chronic hepatitis C infection and a former (peg)interferon alfa-2b-based therapy.

M.R. Kraus, G. Teuber, NN, NN (MPsych), M. Scheurlen

Questions:

  • Neurocognitive and psychiatric changes induced by interferon alfa-2b therapy in patients with chronic hepatitis C - are they fully reversible in long-term follow-up after the end of antiviral treatment?
  • At least 12 months after the end of antiviral treatment - are neurocognitive and mood-related parameters even significantly improved as compared to pretreatment values? Is this possibly only true of patients with successful virus eradication?
  • At least 12 months after the end of antiviral treatment, is there a significant difference between patients with and without sustained virological response with respect to neurocognitive performance, emotional state and quality of life?
  • In the absence of clinically significant liver damage in patients with chronic hepatitis C - does the mere presence of the hepatitis C virus have any significant influence on neurocognitive or attentional performance?
  • Does the study data support an additional indication for antiviral therapy in chronic hepatitis C? In the case of successful virus eradication, emotional state and - above all - is neurocognitive performance significantly improved even in the absence of severe liver damage?

Condition
Hepatitis C, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C Infection and a Former (Peg)Interferon Alfa-2b-Based Therapy

Resource links provided by NLM:


Further study details as provided by University of Wuerzburg:

Enrollment: 197
Study Start Date: July 2005
Study Completion Date: August 2008
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

HCV outpatients (University Hospital)

Criteria

Inclusion Criteria:

  • Patients with chronic hepatitis C and indication for interferon-based antiviral therapy.
  • Written informed consent to study participation, especially to long-term follow-up monitoring of psychiatric and neurocognitive side effects of combination therapy with (peg)interferon alfa-2b and ribavirin.
  • Age of study participants: between 18 and 65 years.
  • All patients need to have documented antibodies to hepatitis C virus (HCV) and circulating HCV-RNA as measured by reverse-transcription polymerase chain reaction (Cobas Amplicor HCV Monitor™ test, Roche Diagnostics)

Exclusion Criteria:

  • Insufficient knowledge of the German language or cognitive impairment (due to the indispensable application of questionnaires and the TAP, test battery of attentional performance).

Further Exclusion Criteria:

  • Age under 18 years or over 65 years
  • Coinfections such as hepatitis B virus or human immunodeficiency virus
  • Severe internal diseases (e.g., cancer, ischemic heart disease, autoimmune disease)
  • Major depressive disorder (according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] criteria), psychosis, active intravenous drug use or alcohol abuse.

These additional exclusion criteria are important in order to avoid interfering or confounding effects by other variables that are not linked to the hepatitis C infection.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00227149

Locations
Germany
Med. Klinik und Poliklinik II, University of Wuerzburg
Wuerzburg, Germany, 97070
Sponsors and Collaborators
University of Wuerzburg
Schering-Plough
Investigators
Principal Investigator: Michael R. Kraus, MD, PhD Med. Klinik und Poliklinik II, University of Wuerzburg
  More Information

Publications:
Responsible Party: Michael R Kraus, MD, PhD, University of Wuerzburg
ClinicalTrials.gov Identifier: NCT00227149     History of Changes
Other Study ID Numbers: PO 4406
Study First Received: September 23, 2005
Last Updated: February 3, 2009
Health Authority: Germany: Ethics Commission

Keywords provided by University of Wuerzburg:
C06.552.380.705.440

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on August 01, 2014